Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coldnil Total is a multi-ingredient oral combination medication manufactured by Modi Lifecare Industries, designed for the symptomatic treatment of the common cold, influenza, and associated respiratory allergies. The formulation typically combines four active pharmaceutical ingredients: paracetamol, phenylephrine hydrochloride, chlorpheniramine maleate, and caffeine. Paracetamol serves as the primary analgesic and antipyretic agent, acting through the inhibition of prostaglandin synthesis. Phenylephrine hydrochloride functions as a decongestant by acting as a selective alpha-1 adrenergic receptor agonist, leading to vasoconstriction in the nasal mucosa. Chlorpheniramine maleate is a first-generation antihistamine that antagonizes H1 receptors to alleviate symptoms such as sneezing, rhinorrhea, and itchy eyes. Caffeine is included as an adjuvant to enhance the analgesic efficacy of paracetamol and to mitigate the sedative effects commonly associated with first-generation antihistamines. As a generic product, Coldnil Total is marketed for the relief of fever, headache, body aches, and nasal congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coldnil Total.